Advertisement
Advertisement
http://2015.eurothrombosis.eu

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH13-11-897
Issue: 2014: 111/6 (June) pp. 1007–1199
Pages: 1067-1076
Ahead of Print: 2014-02-13

Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response

M. E. Mancuso (1), S. Linari (2), A. Aghemo (3), D. Bartolozzi (4), E. Santagostino (1), M. G. Rumi (5), E. Fognani (6), M. R. Fasulo (1), L. Gragnani (6), R. Bruno (7), M. Morfini (2), A. L. Zignego (6), M. Colombo (3)

(1) Angelo Bianchi Bonomi Haemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy; (2) Haemophilia Center, A.O.U. Careggi, Florence, Italy; (3) A.M. Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico and University of Milan, Milan, Italy; (4) Infectious Diseases Unit, University Hospital of Florence, Florence, Italy; (5) Division of Hepatology, Ospedale San Giuseppe and University of Milan, Milan, Italy; (6) Center for Systemic Manifestations of Hepatitis Viruses (MaSVE), Department of Experimental and Clinical Medicine, University of Florence, and Istituto Toscano Tumori (ITT), Florence, Italy; (7) Department of Infectious and Tropical Diseases, Fondazione IRCCS Ospedale San Matteo and University of Pavia, Pavia, Italy

Keywords

Chronic Hepatitis C, Haemophilia, antiviral therapy, interferon lambda 3, spontaneous clearance

Summary

Chronic hepatitis C is the main cause of morbidity and mortality in adult haemophilic patients who received non-virally inactivated plasma-derived clotting factor concentrates. Overall, spontaneous viral clearance rate is 10–25% and the only approach that can halt disease progression is hepatitis C virus (HCV) eradication by means of antiviral therapy. In non-haemophilic patients a single nucleotide polymorphism located upstream the gene of interferon lambda 3 (IFNλ3) has been associated with both spontaneous viral clearance and sustained virological response after antiviral treatment. The aim of this study was to assess whether the rs12979860 polymorphism was a predictor of spontaneous viral clearance and of sustained virological response after antiviral therapy in a large cohort of haemophilic patients with HCV infection. The rs12979860 polymorphism, defined as CC genotype or T allele, was tested in a cohort of 342 haemophilic patients and evaluated as predictor of spontaneous clearance or response to antiviral therapy. By multivariate regression analysis the IFNλ3 CC genotype was an independent predictor of spontaneous viral clearance (odds ratio: 3.7, 95% confidence interval: 2.0–6.8). Sustained virological response rates were doubled in patients with the CC genotype than in those with the T allele (78% vs 44%; p<0.001), especially in patients with HCV type 1 (67% vs 32%; p<0.001) and higher sustained response rates were observed in patients with the CC genotype who did not achieve rapid virological response (61% vs 30% in T allele patients; p=0.006).

You may also be interested in...

1.
U. Scholz1, G. Syrbe2, J. Koscielny3, R. Klamroth4 und das Kompetenznetzwerk Hämorrhagische Diathesen Ost (KHDO)*

Hämostaseologie 2008 28 3: 150-154

2.

M. Cornberg1, 3, 4, J. Wiegand2, 3, 4, K. Deterding1, 3, 4, H. Wedemeyer1, 3, 4

Die Medizinische Welt 2008 59 6: 203-209

3.
Roberto Musso1, Elena Santagostino2, Albert Faradji3, Alfonso Iorio4, Jan van der Meer5, Jørgen Ingerslev6, Thierry Lambert7, Monika Maas-Enriquez8, Eduard Gorina9 for the KOGENATE® Bayer European PMS Study Group*

Thromb Haemost 2008 99 1: 52-58

http://dx.doi.org/10.1160/TH07-06-0409